ReviewSignal transduction and targeted therapy2024
Progression from ductal carcinoma in situ to invasive breast cancer: molecular features and clinical significance.
Review in Signal transduction and targeted therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
81 citing papers in PubMed, 97 citations in OpenAlex.
- Integrated Multi-Omics Reveals Cellular States and Microenvironmental Remodeling in Coexisting DCIS and IDC.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Clinicopathological and Immunohistochemical Correlation of Stromal CD10 Expression in Invasive Breast Carcinoma: A Prospective Observational Study.Iranian journal of pathology · 2026Article
- Cost-effectiveness of mammography-based breast cancer screening in Jordan: a healthcare system perspective.Breast cancer (Tokyo, Japan) · 2026Article
- Deciphering spatial heterogeneity by multimodal spatial transcriptomics modelling with SpatialModal.Bioinformatics (Oxford, England) · 2026Article
- Article
- Translational issues with phototherapy of cancer.Translational oncology · 2026Review
- LYNX: a deep generative model for linking spatial dynamics and cell interactions in multimodal spatial data.bioRxiv : the preprint server for biology · 2026Article
- Multi-modality Graph Representation Learning for Malignant Cell Identification from scRNA-seq using DeepMalignant.bioRxiv : the preprint server for biology · 2026Article
- Deep learning model for noninvasive prediction of Ki-67 expression and prognostic stratification in breast cancer: a multicenter retrospective study.European radiology · 2026Article
- Collagen gene expression profiles predict recurrence and progression of DCIS to IDC.Scientific reports · 2026Article
- Spatiotemporal cell type deconvolution leveraging tissue structure.Research square · 2026Article
- A framework for jointly modeling the natural history of ductal carcinoma in situ and invasive breast cancer.Journal of mathematical biology · 2026Article
- Breast cancer survival prediction using machine learning and multimodal data for personalized care plan.BMC cancer · 2026Article
- Optimal Surgical Margin After Breast-Conserving Surgery in Pure Ductal Carcinoma in Situ: Is a 1 mm Margin Sufficient? A Retrospective Single-Center Cohort Study.Medicina (Kaunas, Lithuania) · 2026Article
- Racial Disparity in Ductal Carcinoma in Situ: Risk-Predictive and Actionable Biomarkers for Early Intervention.Cancers · 2026Review
- New biomarker in the early diagnosis of breast cancer: adiponectin, asprosin, adropin, and resistin.BMC cancer · 2026Article
- Triazole-based inhibitors for breast cancer: biological activity, SAR and synthetic strategies.Molecular diversity · 2026Review
- Transcriptome predictors of second breast events in ductal carcinoma in situ: a case‒control study including Black and White women.Breast cancer research : BCR · 2026Article
- Multicenter development and external validation of clinical-radiomics models to predict surgically confirmed upstaging in biopsy-proven DCIS using DCE-MRI.Journal of applied clinical medical physics · 2026Article
- Prediction of pathologic upstaging in ductal carcinoma in situ using MRI radiomics combined with clinicopathological features.Breast cancer research : BCR · 2026Article
21 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
Abstract
Ductal carcinoma in situ (DCIS) represents pre-invasive breast carcinoma. In untreated cases, 25-60% DCIS progress to invasive ductal carcinoma (IDC). The challenge lies in distinguishing between non-progressive and progressive DCIS, often resulting in over- or under-treatment in many cases. With increasing screen-detected DCIS in these years, the nature of DCIS has aroused worldwide attention. A deeper understanding of the biological nature of DCIS and the molecular journey of the DCIS-IDC transition is crucial for more effective clinical management. Here, we reviewed the key signaling pathways in breast cancer that may contribute to DCIS initiation and progression. We also explored the molecular features of DCIS and IDC, shedding light on the progression of DCIS through both inherent changes within tumor cells and alterations in the tumor microenvironment. In addition, valuable research tools utilized in studying DCIS including preclinical models and newer advanced technologies such as single-cell sequencing, spatial transcriptomics and artificial intelligence, have been systematically summarized. Further, we thoroughly discussed the clinical advancements in DCIS and IDC, including prognostic biomarkers and clinical managements, with the aim of facilitating more personalized treatment strategies in the future. Research on DCIS has already yielded significant insights into breast carcinogenesis and will continue to pave the way for practical clinical applications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.